PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2025
All the vital news, analysis, and commentary curated by our industry experts.
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the anti-TNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets.
Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the RA market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the eight major RA markets from 2015-2025.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Johnson & Johnson
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.4 Quality of Life
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Diagnosed Incidence
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for RA (2015–2025)
4.5.1 Diagnosed Incident Cases
4.5.2 Diagnosed Prevalent Cases
4.5.3 Total Prevalent Cases
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.2 Treatment Guidelines
5.1.3 Leading Prescribed Drugs for the Treatment of RA
5.1.4 Clinical Practice
6 Competitive Assessment
6.2 Product Profiles – Major Brands
6.2.1 Enbrel (etanercept)
6.2.2 Humira (adalimumab)
6.2.3 Remicade (infliximab)
6.2.4 Simponi (golimumab)
6.2.5 Cimzia (certolizumab pegol)
6.2.6 Orencia (abatacept)
6.2.7 Actemra/RoActemra (tocilizumab)
6.2.8 Rituxan/MabThera (rituximab)
6.2.9 Inflectra/Remsima (infliximab biosimilar)
6.2.10 Flixabi (infliximab biosimilar)
6.2.11 Benepali (etanercept biosimilar)
6.2.12 Erelzi (etanercept biosimilar)
6.2.13 Amjevita (adalimumab biosimilar)
6.2.14 Xeljanz (tofacitinib)
6.2.16 Methotrexate (Numerous Brands)
6.3 Biosimilars Assessment
6.3.2 Biosimilars in the Immunology Community
6.3.3 By the Numbers: Biosimilars in Development
6.3.4 The Impact of Biosimilars Is Being Felt Throughout the Pharmaceutical Industry
6.3.5 Uptake of Biosimilars for RA Is Expected to Vary by Market
6.4 Other Therapies
7 Unmet Needs and Opportunities
7.2 Development of Cost-Effective Therapies
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.3 Biomarkers to Predict Responsiveness to Therapy
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.4 Early Diagnosis of RA
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.5 Personalized Treatment Approach
7.5.1 Unmet Need
7.5.2 Gap Analysis
8 Pipeline Assessment
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Class
8.3 Promising Drugs in Clinical Development
8.3.4 Vobarilizumab (ALX-0016)
8.3.6 Pralia (denosumab)
8.3.7 Olumiant (baricitinib)
8.4 Other Drugs in Development
9 Current and Future Players
9.1 Trends in Corporate Strategy
9.2 Company Profiles
9.2.4 Johnson & Johnson
9.2.5 Eli Lilly
9.2.6 Bristol-Myers Squibb
9.2.11 AstraZeneca- MedImmune
9.2.13 Daiichi Sankyo
9.2.14 Samsung Bioepis
10 Market Outlook
10.1 Global Markets
10.1.2 Drivers and Barriers – Global Issues
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5.2 Key Events
10.5.3 Drivers and Barriers
11.4 Forecasting Methodology
11.4.1 Diagnosed RA Patients
11.4.2 Percentage of Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic and Biosimilar Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Primary Research – KOLs Interviewed for This Report
11.6 Primary Research – Prescriber Survey
11.7 About the Authors
11.7.2 Therapy Area Director
11.7.4 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.